CN1042731C - 用作抗肿瘤药的椭圆玫瑰树碱衍生物及其制备方法 - Google Patents

用作抗肿瘤药的椭圆玫瑰树碱衍生物及其制备方法 Download PDF

Info

Publication number
CN1042731C
CN1042731C CN94101690A CN94101690A CN1042731C CN 1042731 C CN1042731 C CN 1042731C CN 94101690 A CN94101690 A CN 94101690A CN 94101690 A CN94101690 A CN 94101690A CN 1042731 C CN1042731 C CN 1042731C
Authority
CN
China
Prior art keywords
protected
substituted
amino
unprotected
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94101690A
Other languages
English (en)
Chinese (zh)
Other versions
CN1099034A (zh
Inventor
辻原健二
原田直之
尾崎邦彦
大桥元明
小田晃司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of CN1099034A publication Critical patent/CN1099034A/zh
Application granted granted Critical
Publication of CN1042731C publication Critical patent/CN1042731C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN94101690A 1993-01-29 1994-01-29 用作抗肿瘤药的椭圆玫瑰树碱衍生物及其制备方法 Expired - Fee Related CN1042731C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP13441/1993 1993-01-29
JP13441/93 1993-01-29
JP1344193 1993-01-29

Publications (2)

Publication Number Publication Date
CN1099034A CN1099034A (zh) 1995-02-22
CN1042731C true CN1042731C (zh) 1999-03-31

Family

ID=11833224

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94101690A Expired - Fee Related CN1042731C (zh) 1993-01-29 1994-01-29 用作抗肿瘤药的椭圆玫瑰树碱衍生物及其制备方法

Country Status (11)

Country Link
US (2) US5565569A (cg-RX-API-DMAC7.html)
EP (1) EP0608876A1 (cg-RX-API-DMAC7.html)
KR (1) KR940018385A (cg-RX-API-DMAC7.html)
CN (1) CN1042731C (cg-RX-API-DMAC7.html)
AU (1) AU666416B2 (cg-RX-API-DMAC7.html)
CA (1) CA2114468A1 (cg-RX-API-DMAC7.html)
FI (1) FI940403A7 (cg-RX-API-DMAC7.html)
IL (1) IL108461A (cg-RX-API-DMAC7.html)
MY (1) MY110683A (cg-RX-API-DMAC7.html)
SG (1) SG42916A1 (cg-RX-API-DMAC7.html)
TW (1) TW269688B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2696465B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2757859B1 (fr) * 1996-12-30 1999-01-29 Adir Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2757858B1 (fr) * 1996-12-30 1999-01-29 Adir Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
US7847109B2 (en) * 2002-05-31 2010-12-07 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
PL1877098T3 (pl) * 2005-05-05 2013-09-30 Glaxosmithkline Ip Dev Ltd Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy
FR2925491B1 (fr) * 2007-12-19 2010-09-03 Oz Biosciences Sas Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933827A (en) * 1974-10-29 1976-01-20 Hoffmann-La Roche Inc. 9-Acyloxy-5,11-dimethyl-6H-pyrido[4,3-B]carbazoles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2308365A2 (fr) * 1975-04-25 1976-11-19 Anvar Derives de l'hydroxy-9 ellipticine et leur application therapeutique
US4310667A (en) * 1976-04-22 1982-01-12 Agence Nationale De Valorisation De La Recherche (Anvar) 2-N Quaternary ammonium salt derivatives of 9-hydroxy ellipticine
JPS6137799A (ja) * 1984-07-31 1986-02-22 Suntory Ltd エリプチシン誘導体およびその製造法
AU4245689A (en) * 1988-10-04 1990-04-12 Suntory Limited Ellipticine glycoside derivatives
JPH05310736A (ja) * 1992-05-06 1993-11-22 Tanabe Seiyaku Co Ltd エリプティシン誘導体、その製法およびその合成中間体
US5272146A (en) * 1992-10-02 1993-12-21 The United States Of America As Represented By The United States Department Of Health And Human Services 1,2-dihydroellipticines with activity against CNS specific cancer cell lines
FR2696465B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933827A (en) * 1974-10-29 1976-01-20 Hoffmann-La Roche Inc. 9-Acyloxy-5,11-dimethyl-6H-pyrido[4,3-B]carbazoles

Also Published As

Publication number Publication date
US5565569A (en) 1996-10-15
CA2114468A1 (en) 1994-07-30
SG42916A1 (en) 1997-10-17
TW269688B (cg-RX-API-DMAC7.html) 1996-02-01
KR940018385A (ko) 1994-08-16
IL108461A (en) 1998-09-24
AU5394794A (en) 1994-08-04
CN1099034A (zh) 1995-02-22
MY110683A (en) 1999-01-30
US5605904A (en) 1997-02-25
FI940403L (fi) 1994-07-30
IL108461A0 (en) 1994-04-12
AU666416B2 (en) 1996-02-08
EP0608876A1 (en) 1994-08-03
FI940403A0 (fi) 1994-01-27
FI940403A7 (fi) 1994-07-30

Similar Documents

Publication Publication Date Title
CN1189469C (zh) 作为抗菌剂的3－(杂芳基乙酰氨基)－2－氧化－氮杂环丁烷－1－磺酸衍生物
CN1105109C (zh) 氯代嘧啶中间体
CN1297564C (zh) 4″－取代－9－脱氧－9a－氮杂－9a－高红霉素A衍生物的制备方法
CN1037683C (zh) 一种三唑基硫甲基硫代头孢菌素氢氯化物的结晶水合物及其制备和其药物组合物
CN1213046C (zh) 四氢吡啶衍生物,它们的制备和它们作为细胞增殖抑制剂的应用
CN1045089C (zh) 2－(2－氨基－1,6－二氢－6－氧代－嘌呤－9－基)甲氧基－1,3－丙二醇衍生物
CN1299280A (zh) 具有抗肿瘤作用的吲哚基－3－乙醛酸衍生物
CN1227542A (zh) 具有抗哮喘、抗过敏和免疫抑制/免疫调节作用的n－取代的吲哚－3－乙醛酰胺类化合物
CN1081187C (zh) 异戊二烯基转移酶抑制剂
CN1283637C (zh) 具有抗肿瘤活性的取代n－苄基吲哚－3－基乙醛酸衍生物
CN1042731C (zh) 用作抗肿瘤药的椭圆玫瑰树碱衍生物及其制备方法
CN1094936C (zh) 新黄酮化合物、制备它们的方法以及含有它们的药物组合物
WO2019026014A1 (en) METHODS FOR PREPARING LIFITEGRAST AND ITS INTERMEDIATES
CN1072652C (zh) 取代的苯甲酰氨基噻唑衍生物以及含有它们的药物
JPS60174787A (ja) ３位置換カルバセフエム化合物
CN1150950A (zh) 头孢菌素衍生物
CN1029965C (zh) 具有氨基噻唑(亚氨基氧基乙酸)乙酸侧链的β-内酰胺的制备方法
CN1037266C (zh) 喹啉衍生物的富马酸盐及其制法和其药物组合物
CN1183778A (zh) 喹啉羧酸衍生物
CN1430621A (zh) 制备乙烯基－吡咯烷酮头孢菌素衍生物的新方法
CN1252072A (zh) 青霉烯化合物、其用途及其中间体化合物
CN101029034A (zh) 多烯紫杉醇水溶性衍生物及制备方法和用途
CN1046716C (zh) 供合成用的新中间体和用于制造氨基哌嗪衍生物的方法
CN1407980A (zh) 杂环衍生物
CN1374864A (zh) 癌的预防剂和治疗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee